Latest news

• Dermira craters as acne drug fails late-stage test

  s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is

• After some big setbacks, Sanofi talks up its R&D portfolio

  antibody Praluent (alirocumab) for cholesterol-lowering, IL4 inhibitor Dupixent (dupilumab) for eczema and IL-6 blocker arthritis treatment Kevzara (sarilumab) as well as a clutch of late-stage pipeline projects - before

• Dupixent dulls pain of diabetes slump at Sanofi

  Dupixent dulls pain of diabetes slump at Sanofi. Biosimilar competition caused steep declines in its flagship product Lantus. ... Accelerating sales of Sanofi’s new atopic dermatitis drug Dupixent helped to offset steep declines in flagship diabetes

• Sanofi, Regeneron claim EU approval for eczema drug Dupixent

  Sanofi, Regeneron claim EU approval for eczema drug Dupixent. Analysts suggest the product could be worth 5bn at peak. ... Dupixent is also being tested for its potential in nasal polyposis, another indication where it could see competition from Nucala.

• Roche out-licenses lebrikizumab rights to Dermira

  Atopic dermatitis has drawn attention in pharma of late largely due to the efforts by Sanofi and Regeneron to develop their IL-4 and IL-13-targeting drug Dupixent (dupilumab) for ... methotrexate. Dupixent seems to be making a great start in the market